DU 257-KM231 antibody conjugate

Drug Profile

DU 257-KM231 antibody conjugate

Alternative Names: DU 257-K231

Latest Information Update: 26 Oct 2006

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 26 Oct 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
  • 03 Apr 2003 No development reported - Preclinical for Cancer in Japan (unspecified route)
  • 05 Mar 2001 Preclinical development for Cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top